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mode of action and the binding site on
the 2 subunit of GABAA receptors?
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ABSTRACT
NA-glycineisanendogenouslipidmoleculewithanalgesicproperties,whichisstruc-
turallysimilartotheendocannabinoids2-AGandanandamidebutdoesnotinteract
with cannabinoid receptors. NA-glycine has been suggested to act at the G-protein
coupled receptors GPR18 and GPR92. Recently, we have described that NA-glycine
can also modulate recombinant 122 GABAA receptors. Here we characterize in
more detail this modulation and investigate the relationship of its binding site with
thatoftheendocannabinoid2-AG.
Subjects Biochemistry, Neuroscience, Pharmacology
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INTRODUCTION
GABA is the major inhibitory neurotransmitter in mammalian brain. Its fast eVects are
mediated by synaptic and extrasynaptic GABAA receptors. These receptors are composed
of ﬁve subunits that surround a central chloride ion channel (Macdonald & Olsen, 1994;
Sieghart, 1995; Sieghart & Sperk, 2002; Sigel & Steinmann, 2012). The major receptor
isoform consists of 1, 2, and 2 subunits (Olsen & Sieghart, 2008). DiVerent approaches
ledtothewidelyaccepted2:2:1 subunitstoichiometry(Changetal.,1996;Tretteretal.,
1997;Farraretal.,1999;Baumann,Baur&Sigel,2001;Baumann,Baur&Sigel,2002;Baur,
Minier & Sigel, 2006) with a subunit arrangement  anti-clockwise as seen from the
synaptic cleft (Baumann, Baur & Sigel, 2001; Baumann, Baur & Sigel, 2002; Baur, Minier
& Sigel, 2006). The pharmacological properties are dependent on subunit composition
(Sigeletal.,1990)andarrangement(Minier&Sigel,2004).
Neurosteroids (Belelli & Lambert, 2005) and the endocannabinoid 2-AG (Sigel et al.,
2011) have been documented as endogenous ligands of GABAA receptors. A binding
site for 2-AG has been shown to be present speciﬁcally on each of the two 2 subunits
present in a pentameric receptor. Moreover it has been proposed that 2-AG dips into
the membrane and binds to the fourth trans-membrane sequence (M4) of 2 subunits
(Bauretal.,2013).
NA-glycine has been shown to be present in amounts of about 50 pmol/g dry weight
in rat brain tissue and about 140 pmol/g dry weight in spinal cord (Huang et al.,
2001). This can be compared to the levels of 2-AG that have been reported to be 4 and
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respectively. Thus, NA-glycine is about 1000-fold less abundant than 2-AG. NA-glycine
has no functional aYnity for CB1 receptors (Sheskin et al., 1997), but may activate the G
protein coupled receptors GPR18 (Kohno et al., 2006) and GPR92 (Oh et al., 2008) and
target NaC=Ca2C-exchanger NCX (Bondarenko et al., 2013) and T-type Ca2C-channels
(Barbara et al., 2009). Interestingly, NA-glycine exerts analgesic properties in diVerent
rodent models of pain (Huang et al., 2001; Succar, Mitchell & Vaughan, 2007). Recently, it
hasbeenreportedthatNA-glycinecanalsointeractwithglycinereceptors,potentiating1
and interestingly inhibiting 2 and 3-containing glycine receptors (Yevenes & Zeilhofer,
2011). It should be noted that NA-glycine functionally interacts with glycine receptors
with an apparent aYnity >10 M. This should be compared to the functional aYnities to
GABAA receptors,NCXandT-typeCa2C-channelsthatareestimated<10M.
We have previously demonstrated that NA-glycine allosterically potentiates GABAA
receptors (Baur et al., 2013), but it remained unclear whether this occurred via the same
binding site as 2-AG. The aim of the present study was therefore to establish whether
NA-glycine acts at the identical site on GABAA receptors as 2-AG. In most studied
aspects Na-glycine acts similar to 2-AG, indicating a common binding site. However,
some point mutations that abrogate modulation by 2-AG leave the initial modulation by
NA-glycine nearly unaVected and only over time the modulation is gradually decreased
to zero. DiVerential solubilization eVects of 2-AG and NA-glycine may account for this
phenomena. Thus, at least during initial phases of interaction with GABAA receptors the
modeofbindingisdiVerentforthetwocompounds.
METHODS
Material
2-AG and NA-glycine were obtained from Cayman Chemical (Chemie Brunschwig, Basel,
Switzerland). All other chemicals, unless mentioned otherwise below, were from Sigma
(Buchs,Switzerland).
Expression of GABAA receptors in Xenopus oocytes
CappedcRNAsweresynthesized(Ambion,Austin,TX,USA)fromthelinearizedplasmids
with a cytomegalovirus promotor (pCMV vectors) containing the diVerent subunits,
respectively. A poly-A tail of about 400 residues was added to each transcript using yeast
poly-A polymerase (United States Biologicals, Cleveland, OH, USA). The concentration
of the cRNA was quantiﬁed on a formaldehyde gel using Radiant Red stain (Bio-Rad
Laboratories, Reinach, Switzerland) for visualization of the RNA. Known concentrations
of RNA ladder (Invitrogen, Life Technologies, Zug, Switzerland) were loaded as standard
on the same gel. cRNAs were precipitated in ethanol/isoamylalcohol 19 : 1, the dried
pellet dissolved in water and stored at  80C. cRNA mixtures were prepared from these
stock solutions and stored at  80C. Xenopus laevis oocytes were prepared, injected
and defolliculated as described previously (Sigel, 1987; Sigel & Minier, 2005; Animal
Permit No. BE98/12, Kantonaler Verterin¨ ardienst, Kanton Bern). They were injected
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2 and wild type 2 subunits at a concentration of 10 nM:10 nM 50 nM (Boileau et
al., 2002) and then incubated in modiﬁed Barth’s solution at C18C for at least 24 h
before the measurements. Where indicated concatenated subunits 1-2-1=2-2 or
1-2-1=2-1 or 1-1-1=2-2 or 1-1-1=2-1 were used at a concentration of
25nM:25nM,each.
Functional characterization of the GABAA receptors
Currents were measured using a modiﬁed two-electrode voltage clamp ampliﬁer Oocyte
clamp OC-725 (Warner Instruments, Camden, CT, USA) in combination with a
XY-recorder (90% response time 0.1 s) or digitized at 100 Hz using a PowerLab 2=20 (AD
Instruments) using the computer programs Chart (ADInstruments GmbH, Spechbach,
Germany). Tests with a model oocyte were performed to ensure linearity in the larger
currentrange.Theresponsewaslinearupto15A.
Electrophysiological experiments were performed using the two-electrode voltage
clamp method at a holding potential of  80 mV. The perfusion medium contained
90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 5 mM Na-HEPES (pH 7.4) and
0.5%DMSOandwasappliedbygravityﬂow6ml/min.Theperfusionmediumwasapplied
through a glass capillary with an inner diameter of 1.35 mm, the mouth of which was
placed about 0.4 mm from the surface of the oocyte. Allosteric modulation via the 2-AG
site was measured at a GABA concentration eliciting about 1% of the maximal GABA
current amplitude (EC1). In each experiment, 1 mM GABA was applied to determine
the maximal current amplitude. Subsequently increasing concentrations of GABA were
applied until 0.5%–1% of the maximal current amplitude was elicited (0.3–3 M). For
modulationexperiments,GABAwasappliedfor20saloneorincombinationwith2-AGor
NA-glycine. 2-AG or NA-glycine were pre-applied for 30 s. Modulation of GABA currents
was expressedas (I.modulatorCGABA/=IGABA–1)100%. Inhibitionby DEAwas determined
at the end of a 1 min co-application with either NA-glycine or 2-AG following a 30 s
pre-application of both compounds. The perfusion system was cleaned between drug
applicationsbywashingwithdimethylsulfoxidetoavoidcontamination.
Determination of critical micelle concentrations (CMC)
Assays were performed as reported previously (Raduner et al., 2007). In brief, compounds
(from 2 mM stock solutions) were incubated at increasing concentrations with 0.1 nM
ﬂuorescein (free acid, 99%, Fluka, Switzerland) for 90 min at 30C in Nanopure distilled
water. Experiments were carried out on 96-well microtiter plates (excitation at 485 nm,
emission at 535 nm) on a TECAN Farcyte reader. Experiments were performed in
triplicatesinthreeindependentexperimentsanddataaremeanvaluesS.D.
RESULTS
BothNA-glycineand2-AGallostericallypotentiaterecombinant122 GABAA receptors
expressed in Xenopus oocytes. Both compounds share the arachidonoyl tail structure
but diVer in their hydrophilic head groups (Fig. 1). Please note that at physiological pH,
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 3/15Figure1 ChemicalstructureofNA-glycineand2-AG.
NA-glycineisnegativelycharged.HerewewantedtocomparetheGABAA receptorbinding
siteforNA-glycinewiththewell-characterizedbindingsitefor2-AG.
Figure 2A shows current traces of a cumulative concentration–response curve of the
allosteric potentiation of 122 GABAA receptors at a GABA concentration of 1 M. At
the highest concentration used the current trace displayed the typical signs of an open
channelblock,rapidapparentdesensitizationandanoVcurrent.Thisphenomenonmade
a precise curve ﬁt impossible as maximal potentiation could not be determined precisely.
The averaged concentration–response curve (Fig. 2B) was ﬁtted with the assumption of
diVerentmaximalpotentiation.FromtheseﬁtsitwasestimatedthattheEC50 wasbetween
1 and 10 M (not shown). Direct activation by 3 M NA-glycine elicited no signiﬁcant
current(<2nA)inoocyteswhere100MGABAelicitedacurrent>7A.
Allosteric potentiation by 3 M NA-glycine was determined at diVerent concentrations
of the endogenous agonist GABA. Figure 3 shows that the degree of potentiation was
rapidly decreasing with increasing concentrations of GABA. The comparable properties
of 2-AG are also shown in Fig. 3. We tried to rationalize these ﬁndings using a model that
has previously been proposed on the basis of other observations (Baumann, Baur & Sigel,
2003;Fig.4A).ThismodelassumesbindingofGABAtotwositesdiVeringintheirbinding
aYnityandtransitiontotheopenstatewithlowpropensityofsinglyligatedstatesandhigh
propensity of the doubly ligated state. Figure 4B shows computed current amplitudes in
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 4/15Figure 2 Concentration-dependent potentiation of currents mediated by recombinant 122
GABAA receptors. (A) Receptors were expressed in Xenopus oocytes and currents were measured by
usingelectrophysiologicaltechniquesataGABAconcentrationeliciting0.5–1.0%ofthemaximalcurrent
amplitude (EC0:5–1:0/. GABA was applied twice (single bars) and subsequently in combination with
increasing concentrations of NA-glycine. The numbers above the double bars indicate the concentration
of NA-glycine in M. NA-glycine was pre-applied for 30 s. Original current traces are shown. (B) shows
the averaged concentration-dependent potentiation of currents elicited by GABA by NA-glycine. Four
experiments as shown under (A) were averaged. Data are shown as mean  SD (nD4). Such an averaged
curve has been shown before based on 3 experiments and missing the point at 10 M NA-glycine
(Baur et al., 2013).
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 5/15Figure 3 Inﬂuence of the GABA concentration. Current potentiation by 3 M NA-glycine (closed
circles) or 2-AG (closed squares) was determined at diVerent concentrations of GABA. Potentiation
decreased with increasing concentrations of GABA. The GABA concentration response curve was ﬁtted
with a mean EC50 of 35 M and a mean Hill coeYcient of 1.5 (not shown).
dependenceoftheGABAconcentration.Inaddition,apredictedcurveisshownwhereitis
assumedthatNA-glycinepromotestransitionofthesinglyligatedreceptorfromtheclosed
to the open state. Figure 4C shows a computed GABA concentration-dependence of the
currentpotentiationexpectedinthiscase.Themodelpredictsthatsizeablepotentiationis
limitedtoverylowconcentrationsofGABA.
We have previously shown that the CB1 receptor ligand DEA antagonizes potentiation
by 2-AG (Baur et al., 2013). Therefore, we compared the ability of DEA to antagonize
potentiation by NA-glycine and 2-AG. Based on the structural similarity of the three
compounds we assumed a competitive behaviour. Figure 5 compares the cumulative
concentration inhibition curves for 3 M NA-glycine and for 3 M 2-AG. Potentiation
byNA-glycinewasinhibitedhalf-maximallyat7236M(n D 4)DEAandpotentiation
by 2-AG at 1.4  0.6 M (n D 6). If the two ligands displayed a similar apparent aYnity
for potentiation at the same site where DEA acts, providing equal water solubility and
lipid solubilization, a similar inhibitory potency of DEA would have been expected. In
order to investigate if DEA and NA-glycine act competitively, we repeated a concentration
inhibition curves at 6-times lower concentration (0.5 M) of NA-glycine. Half-maximal
inhibition was observed at 96  41 M (n D 4) DEA (Fig. 5). This could be interpreted
as non-competitive interaction of DEA with NA-glycine. Similarly, we performed
concentration inhibition curves at 1 and 15 M 2-AG. The higher concentration of 2-AG
elicits direct current that amount to less than 0.1% of the maximal current amplitude
elicited by GABA in the same oocytes. As expected for a competitive interaction between
2-AG and DEA, half-maximal inhibition was shifted to the left upon decrease of the
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 6/15Figure 4 Mode of action of NA-glycine. Simpliﬁed model (A) The model assumes two agonist binding
sites 1 and 2 with diVerent aYnities. 2-AG aVects the closed/open transition of the two singly ligated
states. The receptor R can ﬁrst bind GABA (A) either to the site 1 (AR) or the site 2 (RA). The receptor
occupied by two agonist molecules ARA can isomerize to the open state ARA*, the receptors occupied
by a single agonist molecule can isomerize to the open states AR* and RA*. Binding is described with K
as dissociation constants and gating with L as closed state/open state equilibrium. (C) Theoretical GABA
concentrationresponsecurvesintheabsenceandpresenceofNA-glycine.Thefollowingparameterswere
assumed: 0.24 for L, 10 and 2.2 for L1 in the absence and presence of NA-glycine, respectively, 11 and 2.4
for L2 in the absence (line) and presence (dashed line) of NA-glycine, respectively, 30 M for K1, 90 M
for K2. (C) Dependence of the potentiation by NA-glycine on the concentration of GABA obtained by
the ratio of the computed current in the presence of NA-glycine divided by the current in its absence.
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 7/15Figure 5 Concentration inhibition curve of DEA. Increasing concentrations of DEA were co-applied
with 1 M 2-AG (open circles), 3 M 2-AG (open squares), 15 M 2-AG (open diamonds), 0.5 M
NA-glycine (ﬁlled circles), or 3 M NA-glycine (ﬁlled squares). Data are shown as mean  SEM .n D 4/.
2-AG concentration from 3 M to 1 M, but the inhibition curve became much ﬂatter,
indicating the DEA becomes partially inactive at higher concentrations. Half-maximal
inhibition for 15 M was not reached at concentrations up to 100 M (n D 4) DEA
(Fig. 5). In case of a non-competitive interaction of DEA with 2-AG an IC50 of about
1.4 M and in case of a competitive interaction an IC50 of about 7 M would be expected
in the latter case. The observed results cannot be explained by classical receptor theory
and we therefore speculate that 2-AG and NA-glycine exhibit a diVerent water solubility
and lipid solubilisation in the experimental setup. In the discussion we mention possible
explanations.
NA-glycine shows higher eYcacy than 2-AG for potentiation of currents elicited by
GABA. 2-AG is metabolically stable in Xenopus oocytes as no degradation by serine
hydrolases was found (not shown). In case NA-glycine competes for the same binding site
as2-AGandbothmoleculeshaveasimilarapparentaYnitytothisbindingsite,itwouldbe
anticipatedthatthedegreeofpotentiationbybothagentsatthesameconcentrationwould
result in an intermediate potentiation as compared to the individual agents. The apparent
aYnity of 2-AG has been determined as 2 M, while the apparent aYnity of NA-glycine is
estimated1–10Mhere.AsshowninFig.6A,combinedapplicationresultssurprisinglyin
nearlythesameextentofpotentiationasapplicationofNA-glycinealone.
Again, this may be caused by a diVerential water solubility and membrane solubil-
isation behaviour of NA-glycine and 2-AG. We therefore measured the critical micelle
concentrations of both molecules. The apparent CMC was >100 M for NA-glycine and
4.2  0.5 M for 2-AG, pointing to signiﬁcant self-assembly and detergent behaviour of
2-AG.
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 8/15Figure6 EVectofsubunitcombinationandco-applicationwith2-AG. (A) Current potentiation by the
combined application of 3 M NA-glycine and 3 M 2-AG is compared with the individual application
of the two substances. (B) Current potentiation by 3 M NA-glycine in 122 receptors and 112
receptors. Potentiation is strongly dependent on the presence of the 2 subunit.
As 2-AG fails to potentiate in GABAA receptors where the 2 subunit is replaced by
1, we tested potentiation by NA-glycine in 112 receptors (Fig. 6B). Similarly to
2-AG, potentiation by NA-glycine depends on the presence of 2 subunits. We studied
potentiation by NA-glycine in concatenated receptors containing either two 2 subunits,
two 1 subunits or one each 1 and 2 in diVerent positions in the receptor pentamer
(Fig. 7). Receptors containing two 2 subunits exhibited strong potentiation while
receptors containing two 1 subunits showed very weak potentiation. Intermediate
potentiation was observed in receptors containing one each, 1 and 2. This strongly
indicatesthattheNA-glycinebindingsiteislocatedonthe2 subunitaspreviouslyshown
with2-AG(Sigeletal.,2011).
A number of point mutations have been described to interfere with the potentiation by
2-AG. We tested the eVect of the point mutations2W428C,2S429C,2F432C,2F439L
and 2V443C. Original current traces are shown for the mutant receptor 12S429C2.
These traces are compared with traces from wild type receptors (Fig. 8A). While wild type
receptorsshowatime-independentpotentiationbyNA-glycine,mutantreceptorsshowed
initially a potentiation that rapidly decayed over time. As these mutant receptors show a
similar dependence on GABA as wild type receptors, and the experiment were carried out
atverylowGABAconcentrationsthiscurrenttransientisnotduetodesensitization.Inthe
case of 2-AG the eVect of these mutations is a reduction of the potentiation independent
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 9/15Figure7 Concentration-dependentpotentiationofcurrentsmediatedbyconcatenatedGABAA recep-
tors. Concatenated 1-1-1=2-1, 1-1-1=2-2, 1-2-1=2-1 or 1-2-1=2-2 receptors
were expressed in Xenopus oocytes and currents were measured at a GABA concentration eliciting
0.5–1.0% of the maximal current amplitude (EC0:5–1:0). Current potentiation by increasing concen-
trations of NA-glycine was determined. Four such experiments were averaged. Data are shown as mean
 SD (n D 4).
of the time of exposure to 2-AG. This behaviour is observed with NA-glycine for the
potentiationof12F432C2 receptors,butnottheothermutantreceptorsstudied.
ThemutationstudiesindicateasiteofactionintheinnerleaﬂetofM4ofthe2 subunit.
In this case NA-glycine has to traverse the lipid bilayer either by diVusion or mediated by
a transport system and this may require some time. In order to test the time-dependence
ofactionofNA-glycineweexposedanoocytetoGABAfollowedbyGABAandNA-glycine
(Fig. 9). Indeed, onset of modulation was slow and did not reach a steady level within
1 min. Upon switch of the medium to GABA only, a slow decay of the potentiation was
observed.
DISCUSSION
NA-glycine allosterically potentiates GABAA receptors like the major endocannabinoid
2-AG. We aimed at localizing the site of interaction of Na-glycine with recombinant
122 GABAA receptors relative to the site for 2-AG. An interpretation of our results
ishampered bythe factthat theapparent aYnityfor thepotentiation byNA-glycine could
not be determined accurately. However, we can estimate this value to be in the range of
1–10 M, which compares well with the value of 2 M for 2-AG (Sigel et al., 2011). The
factthatweﬁndsigniﬁcantpotentiationofGABAA receptorsby>0.1MNA-glycinemay
reﬂect the better water solubility of NA-glycine over 2-AG at low concentrations and even
indicate biological relevance as the average in vivo concentration in the central nervous
systemmaybeestimatedfromthedrytissuecontentasabout15–50nMandNA-glycineis
unlikelytoberandomlydistributed.
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 10/15Figure 8 EVect of point mutations that reduced potentiation by 2-AG on the potentiation of NA-
glycine. (A) Potentiation by 3 M NA-glycine is compared between wild type receptors and receptors
containingthepointmutationS429Cinthe2 subunit.Thismutationresultsatthebeginningofthedrug
application in an about 50% reduction of potentiation and after 1 min drug application potentiation is
abolished.(B)Wildtypereceptorsarecomparedwithmutantreceptors.Currentpotentiationisindicated
at the beginning of the drug application (ﬁlled bars) and after 1 min drug exposure (open bars).
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 11/15Figure 9 Time course of the potentiation by NA-glycine. An oocyte expressing 122 receptors was
sequentially exposed to medium alone, to 1 M GABA, to the same concentration of GABA in combina-
tion with 5 M NA-glycine, to 1 M GABA alone and the to medium. This experiment was repeated two
more times with similar results.
ThefollowingobservationsargueforasimilarmodeofactionofNA-glycineand2-AG.
First, both substances only act exclusively at low GABA concentration (Fig. 3), putatively
by enhancing the opening of singly ligated receptor channels (Fig. 4). A leftward shift of
the concentration response curve for GABA as observed in the case of benzodiazepines
does not abrogate potentiation below EC50 (Sigel & Steinmann, 2012). To our knowledge,
thisisanewmodeofactionofaligand.Second,investigationofreceptorswithdiVerent
subunits (Fig. 5) and experiments with concatenated receptors containing either no, one,
or two 2 subunits (Fig. 6) strongly indicate that both ligand binding sites are located on
the 2 subunit. A common binding site in the inner leaﬂet of the fourth trans-membrane
region(M4)ofthissubunitissuggestedbythefactthatmodulationbybothagentsiseither
reducedorabolishedinﬁveidenticalmutantreceptors,atleastinthelatephaseofactionof
NA-glycine(Fig.8B).Theonsetofactionforbothsubstanceswasfoundtobeslow(Fig.9;
Baur et al., 2013). On the basis of these observations, it is tempting to assume a common
bindingsiteforthetwoligands.
The following observation cannot be explained by classical receptor theory in case
NA-glycine and 2-AG use an identical binding site, i.e., display a similar apparent
aYnity and interact with each other in a competitive way. Combined application of two
compounds with similar aYnities at identical concentrations is then expected to result in
an intermediate potentiation as compared to that by individual compounds. Instead, the
observed potentiation is similar to the one by NA-glycine alone. A second observation is
diYculttoreconcilewithacommonbindingsiteforNA-glycine,2-AGandtheinhibitorof
thepotentiation of2-AG,DEA. Namely, DEApreventspotentiation byNA-glycineonly at
50-fold higher concentrations as that caused by 2-AG. As mentioned in the result section,
the interaction between DEA and 2-AG cannot be explained by classical receptor theory.
Since NA-glycine exerts a signiﬁcant higher CMC than 2-AG, diVerential solubilisation of
NA-glycine and 2-AG with Xenopus oocytes may account for some of the eVects observed
in this study. The way these lipids are organized in an aqueous environment will aVect
entry of the molecules into the bilayer, binding equilibrium, and the way the receptor is
occupied. If this holds true the observations with co-application of NA-glycine and 2-AG
as well as the inhibition of NA-glycine and DEA have to be seen in a new light. In spite of
Baur et al. (2013), PeerJ, DOI 10.7717/peerj.149 12/15our observations the three agents could still all bind to largely overlapping sites within an
extendedsurfaceabletobindﬂexiblehydrophobicstructures.
The mutant receptors 12W428C2, 12S429C2, 12F439L2 and 12V443C2
all largely abrogate modulation by NA-glycine after 1 min of combined application of
GABA with NA-glycine. This abrogation is not present at the beginning of the combined
application, but sets in rather slowly. We have no explanation for this observation.
Solubilityconsiderationsdonothelptoexplainthisphenomenon.
Overall,mostargumentspointtoasimilaractionandpossiblyoverlappingbindingsite
for NA-glycine and 2-AG. No matter what the exact mode of interaction of NA-glycine
with the GABAA receptor is, this agent represents by far the stronger positive allosteric
modulator than 2-AG, although the latter is more abundant in brain. The implications of
ourﬁndingsfortheanalgesiceVectofNA-glycineremaintobestudied.
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